Orchid Pharma, a subsidiary of India’s Dhanuka Labs, has gained a sublicense to manufacture the antibiotic cefiderocol as part of an effort to expand access worldwide.
Orchid Pharma, the Chennai-based drug maker on Tuesday said it has entered into a technology transfer agreement with a leading multinational biotechnology company for its fermentation based ‘7ACA project’ under the production linked incentive (PLI) scheme. nnnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/orchid-pharma-enter-tech-transfer-pact-to-make-key-cephalosporin-intermediate/articleshow/101676645.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Orchid Pharma Limited has posted net profit of Rs. 59.13 crores for the period ended March 31, 2023 as against net profit of Rs. 7.58 crores for the period ended December 31, 2022. The company posted net loss of Rs. 6.58 crores for the period ended March 31, 2022.
2 hours ago — New Delhi: Drug firm Orchid Pharma on Thursday said its board has approved raising Rs 500 crore from institutional investors.
Orchid Pharma, which was taken over by Dhanuka Laboratories under insolvency resolution in March 2020, is making a turn-around in revenue and profit as it commercialises a molecule developed in-house, said its senior executive.
Fuelled by increasing sales and a laser sharp focus on costs, Orchid Pharma reported a 36% surge in total revenue from operations while the EBIDTA has jumped by 104% in the quarter ended 30 September 2022 over the quarter ending September 2021.
India’s largest drugmaker, Sun Pharmaceutical Industries, is expanding in the Japanese market when most of its peers have indicated they are not bullish on it.
Orchid Hlthcare’S Generic Risedronate SodiumApproval In US
CHENNAI: The Chennai bench of the National Company Law Tribunal (NCLT) has shot down a proposal by Ingen Capital to take over Orchid Pharma after it failed to bring in the requisite money. The bench also ordered the entire process to restart with fresh deadlines.
Lenders to bankrupt Orchid Pharma have called for a second round of bidding for the drug maker after they found the offer from the only eligible bidder in the first round — Union Quimico Farmacéutica — to be too low, two senior officials said.